Last reviewed · How we verify
NCT04576754
Pivotal Test: WB001
NA trial testing WB001 in Postpartum Depression in 83 participants. Completed in 20 August 2021.
14 June 2021
Quick facts
| Lead sponsor | Woebot Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 83 |
| Start date | 12 November 2020 |
| Primary completion | 14 June 2021 |
| Estimated completion | 20 August 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- WB001
- Educational
Conditions studied
- Postpartum Depression — all drugs for Postpartum Depression →
Sponsor
Woebot Health
Who can join
Adults 18 to 45, female only, with Postpartum Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the present randomized controlled study is to investigate if there is a difference in postpartum depression symptoms among participants assigned to : 1. an automated conversational agent based on the most researched and scientifically validated psychotherapies, primarily Cognitive Behavioral Therapy (CBT), and accessible via an iOS and Android application, or to 2. a comparison condition without CBT and conversation, though still delivered in an interactive smartphone application that is accessible anytime of day.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04576754
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of WB001
Trials testing the same drug.
- NCT05551195 — [Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression] · NA · terminated
Other recruiting trials for Postpartum Depression
Currently open trials in the same condition.
- NCT07398469 — A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone · recruiting
- NCT06442774 — MamaConecta: Digital Tool for Maternal Mental Health · NA · recruiting
- NCT06545760 — Admission to Kangaroo Mother Care (KMC) Ward and Maternal Postpartum Depression · NA · recruiting
- NCT05763537 — Understanding the Role of Doulas in Supporting People With PMADs · NA · recruiting
- NCT06462638 — COntact RElationship in Neonatal Intensive Care Unit · recruiting
Other Woebot Health trials
Trials by the same sponsor.
- NCT06240091 — Potency and Precision Investigation · NA · completed
- NCT05948670 — Participant Satisfaction With the BUILD Mobile Application · NA · completed
- NCT05662605 — W-PPMA for Postpartum Mothers · NA · terminated
- NCT05693792 — A Six-Month Prospective Follow-Up Study of WB001 · withdrawn
- NCT05551195 — [Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression] · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04576754 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Woebot Health
- Last refreshed: 14 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04576754.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing